Doctor Bio:
Nisha Joseph, MD is an Assistant Professor at the Department of Hematology and Medical Oncology Winship Cancer Institute in Emory University, Atlanta GA.
Response Rates Among t(11; 14) MM Patients Receiving Triplet Induction Therapy Presented at ASCO 2022
Dr. Nisha Joseph Discusses Response Rates Among t(11; 14) MM Patients Receiving Triplet Induction Therapy
Abstract Title:
Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy.
What is the purpose of this trial?
The presence of t(11;14) on plasma cells by Fluorescence in Situ Hybridization (FiSH) or metaphase cytogenetics is considered a standard-risk prognostic factor (per IMWG risk-stratification). However, recent studies suggest inferior progression-free survival (PFS) and overall survival (OS) observed among t(11;14) patients relative to the standard-risk myeloma patients.
In the context of the ongoing trials of BCL-2 inhibitors (venetoclax) among t(11;14) relapse/refractory myeloma (RRMM) patients yielding response rates closer to 90%, we review the prognostic impact of t(11;14) on PFS. These results may have implications for earlier incorporation of BCL-2 inhibitors among t(11;14) myeloma patients.
In this video:
Nisha Joseph, MD (Winship Cancer Institute, Emory University—Atlanta, GA) discusses response rates and prognostic impact of t(11; 14) among myeloma patients receiving triplet induction therapy.
Conclusion:
Even with the use of modern-day induction regimens and transplant, MM patients with t(11;14) seem to have inferior response rates compared to other standard-risk myelomas. The lower rates of ≥ very good partial response (VGPR) post-induction and the shorter median PFS suggest BCL-2 inhibitors such as venetoclax may be incorporated earlier in myeloma treatments to improve the outcomes of t(11;14) patients on par with the other standard-risk myeloma patients.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
